Evidence map›Paper›PMID 39095465›Full record

ArticleNPJ breast cancer2024

Impact of systemic disease on CNS disease control after stereotactic radiosurgery to breast cancer brain metastases (The SYBRA Study).

Alex Schick, Sara Hardy, Myla Strawderman, Dandan Zheng, Michael Cummings, Michael T Milano, Allison Magnuson, Jacqueline Behr, Sarah Sammons, Kenneth Usuki and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ breast cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Alex SchickDivision of Hematology/Oncology, Department of Medicine & Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.ORCID http://orcid.org/0000-0003-3015-9138
Sara HardyDepartment of Radiation Oncology, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
Myla StrawdermanDepartment of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY, USA.ORCID http://orcid.org/0000-0002-6016-968X
Dandan ZhengDepartment of Radiation Oncology, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
Michael CummingsDepartment of Radiation Oncology, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
Michael T MilanoDepartment of Radiation Oncology, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
Allison MagnusonDivision of Hematology/Oncology, Department of Medicine & Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
Jacqueline BehrDivision of Neuro-Oncology, Department of Neurology & Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
Sarah SammonsDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-2589-9422
Kenneth UsukiDepartment of Radiation Oncology, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
Nimish MohileDivision of Neuro-Oncology, Department of Neurology & Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
Ruth O'ReganDivision of Hematology/Oncology, Department of Medicine & Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
Carey K AndersDivision of Medical Oncology, Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA.ORCID http://orcid.org/0000-0001-9165-4074
David HicksDepartment of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA.
Ajay DhakalDivision of Hematology/Oncology, Department of Medicine & Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA. ajay_dhakal@urmc.rochester.edu.ORCID http://orcid.org/0000-0002-5140-158X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objective of the study is to assess impact of systemic disease (SD) status on overall survival and brain metastasis (BM) control, adopting a novel landmark approach to categorize SD among breast cancer (BC) patients. This single institution retrospective study included BCBM patients who have received stereotactic radiosurgery (SRS) to brain. Separate endpoints [CNS failure-free survival (cFFS), overall survival (OS)] were analyzed from each Landmark (LM): LM1 (3-months), LM2 (6-months). Patients were categorized into early and non-early progression (EP, NEP) groups depending on SD status before LMs. Median survivals from LM were assessed with Kaplan Meier plots, compared with Log-Rank test. EP was associated with worse median cFFS and OS vs NEP in both LM analyses (cFFS- LM1: 3.6 vs. 9.7 months, p = 0.0016; LM2: 2.3 vs. 12.5 months, p < 0.0001; OS- LM1: 3.6 vs. 24.3 months, p < 0.0001; LM2: 5.3 vs. 30.2 months, p < 0.0001). In multivariate analyses, EP was associated with shorter cFFS [LM1: Hazard Ratio (HR) with 95% confidence interval (CI) 3.16, 1.46-6.83, p = 0.0034; LM2: 5.32, 2.33-12.15, p = <0.0001] and shorter OS (LM1: HR with 95% CI 4.28, 1.98-9.12, p = 0.0002; LM2: 7.40, 3.10-17.63, p = <0.0001) vs NEP. Early systemic disease progressions after 1st SRS to brain is associated with worse cFFS and OS in patients with BCBM.

Identifiers

PMID39095465
PMCPMC11297231

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.